136 related articles for article (PubMed ID: 11971941)
1. Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test.
Chan DC; Watts GF; Barrett PH; Martins IJ; James AP; Mamo JC; Mori TA; Redgrave TG
J Lipid Res; 2002 May; 43(5):706-12. PubMed ID: 11971941
[TBL] [Abstract][Full Text] [Related]
2. Does pravastatin increase chylomicron remnant catabolism in postmenopausal women with type 2 diabetes mellitus?
Ng TW; Watts GF; Stuckey BG; Ching HL; Chan DC; Uchida Y; Sakai N; Yamashita S; Martins IJ; Redgrave TG; Barrett PH
Clin Endocrinol (Oxf); 2005 Dec; 63(6):650-6. PubMed ID: 16343099
[TBL] [Abstract][Full Text] [Related]
3. Preliminary experience with a new stable isotope breath test for chylomicron remnant metabolism: a study in central obesity.
Watts GF; Chan DC; Barrett PH; Martins IJ; Redgrave TG
Clin Sci (Lond); 2001 Dec; 101(6):683-90. PubMed ID: 11724657
[TBL] [Abstract][Full Text] [Related]
4. Effect of Simvastatin on markers of triglyceride-rich lipoproteins in familial hypercholesterolaemia.
Dane-Stewart CA; Watts GF; Mamo JC; Barrett PH; Martins IJ; Dimmitt SB; Redgrave TG
Eur J Clin Invest; 2002 Jul; 32(7):493-9. PubMed ID: 12153549
[TBL] [Abstract][Full Text] [Related]
5. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity.
Chan DC; Watts GF; Barrett PH; Mamo JC; Redgrave TG
Clin Chem; 2002 Feb; 48(2):278-83. PubMed ID: 11805008
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
7. Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia.
Boquist S; Karpe F; Danell-Toverud K; Hamsten A
Atherosclerosis; 2002 May; 162(1):163-70. PubMed ID: 11947910
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin enhances the plasma clearance of chylomicron-like emulsions in subjects with atherogenic dyslipidemia: relevance to the in vivo metabolism of triglyceride-rich lipoproteins.
Sposito AC; Santos RD; Amâncio RF; Ramires JA; Chapman MJ; Maranhão RC
Atherosclerosis; 2003 Feb; 166(2):311-21. PubMed ID: 12535744
[TBL] [Abstract][Full Text] [Related]
9. Chylomicron remnant metabolism in familial dyslipidemias studied with a remnant-like emulsion breath test.
Redgrave TG; Watts GF; Martins IJ; Barrett PH; Mamo JC; Dimmitt SB; Marais AD
J Lipid Res; 2001 May; 42(5):710-5. PubMed ID: 11352977
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
Chan DC; Watts GF; Barrett PH; Mori TA; Beilin LJ; Redgrave TG
J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377
[TBL] [Abstract][Full Text] [Related]
11. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
Chan DC; Watts GF; Barrett PH; Beilin LJ; Redgrave TG; Mori TA
Diabetes; 2002 Aug; 51(8):2377-86. PubMed ID: 12145148
[TBL] [Abstract][Full Text] [Related]
12. Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients.
Parhofer KG; Laubach E; Barrett PH
J Lipid Res; 2003 Jun; 44(6):1192-8. PubMed ID: 12671031
[TBL] [Abstract][Full Text] [Related]
13. Chylomicron remnant metabolism studied with a new breath test in postmenopausal women with and without type 2 diabetes mellitus.
Dane-Stewart CA; Watts GF; Barrett PH; Stuckey BG; Mamo JC; Martins IJ; Redgrave TG
Clin Endocrinol (Oxf); 2003 Apr; 58(4):415-20. PubMed ID: 12641623
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity.
Chan DC; Watts GF; Mori TA; Barrett PH; Redgrave TG; Beilin LJ
Am J Clin Nutr; 2003 Feb; 77(2):300-7. PubMed ID: 12540386
[TBL] [Abstract][Full Text] [Related]
15. Relationships between cholesterol homoeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome.
Chan DC; Watts GF; Barrett PH; O'Neill FH; Redgrave TG; Thompson GR
Clin Sci (Lond); 2003 Apr; 104(4):383-8. PubMed ID: 12653682
[TBL] [Abstract][Full Text] [Related]
16. Effect of pravastatin on plasma removal of a chylomicron-like emulsion in men with coronary artery disease.
Santos RD; Sposito AC; Ventura LI; Cesar LA; Ramires JA; Maranhão RC
Am J Cardiol; 2000 May; 85(10):1163-6. PubMed ID: 10801994
[TBL] [Abstract][Full Text] [Related]
17. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity.
Chan DC; Watts GF; Mori TA; Barrett PH; Beilin LJ; Redgrave TG
Eur J Clin Invest; 2002 Jun; 32(6):429-36. PubMed ID: 12059988
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects.
Parhofer KG; Barrett PH; Schwandt P
J Clin Endocrinol Metab; 2000 Nov; 85(11):4224-30. PubMed ID: 11095458
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets.
Kappelle PJ; Dallinga-Thie GM; Dullaart RP;
Biochim Biophys Acta; 2010 Jan; 1801(1):89-94. PubMed ID: 19800983
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern.
O'Keefe JH; Captain BK; Jones PG; Harris WS
Prev Cardiol; 2004; 7(4):154-60. PubMed ID: 15539961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
